PMID- 28245833
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20181113
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 10
IP  - 1
DP  - 2017 Feb 28
TI  - A hybrid of B and T lymphoblastic cell line could potentially substitute 
      dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T 
      lymphocytes from advanced breast cancer patients in vitro.
PG  - 63
LID - 10.1186/s13045-017-0429-8 [doi]
LID - 63
AB  - Adoptive transfer of cytotoxic T lymphocytes (CTLs) holds promises to cure 
      cancer. However, this treatment is hindered by lacking a robust way to 
      specifically expand out CTLs. Here, we developed a hybrid of B lymphoblastic cell 
      line and T lymphoblastic cell line (T2 cells) as a substitute of dendritic cells, 
      together with irradiated autologous peripheral blood mononuclear cell (PBMC) as 
      feeder cells and rhIL-2, to activate and expand Her-2/neu-specific CD8(+) T cells 
      from human epidermal growth factor receptor 2 (Her-2/neu) and human leukocyte 
      antigen (HLA)-A2 double positive advanced breast cancer patients in vitro. These 
      Her-2/neu-loaded T2 cells reproducibly activated and expanded out 
      Her-2/neu-specific CD8(+) T cells to 10(7) in 8 weeks. Furthermore, these 
      Her-2/neu-specific CD8(+) T cells had good sensitivity of recognition and killing 
      Her-2/neu-overexpressed breast cancer cell line SK.BR.3. This technique gives us 
      another insight on how to rapidly obtain sufficient CTLs for adoptive cancer 
      immunotherapy.
FAU - Chen, Sheng
AU  - Chen S
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Gu, Feifei
AU  - Gu F
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Li, Kang
AU  - Li K
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Liu, Yangyang
AU  - Liu Y
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Liang, Jinyan
AU  - Liang J
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Gao, Wei
AU  - Gao W
AD  - Traumatology Department, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Wu, Gang
AU  - Wu G
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China.
FAU - Liu, Li
AU  - Liu L
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, China. liulist2013@163.com.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20170228
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antigens, Neoplasm)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Breast Neoplasms/immunology/*therapy
MH  - Cell Culture Techniques/methods
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Dendritic Cells
MH  - Female
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Receptor, ErbB-2/*immunology
MH  - T-Lymphocytes, Cytotoxic/cytology/immunology/*transplantation
PMC - PMC5331710
OTO - NOTNLM
OT  - Adoptive cancer immunotherapy
OT  - Breast cancer
OT  - Cytotoxic T lymphocytes
OT  - Hybrid of B and T lymphoblastic cell line
EDAT- 2017/03/02 06:00
MHDA- 2017/12/06 06:00
PMCR- 2017/02/28
CRDT- 2017/03/02 06:00
PHST- 2017/01/07 00:00 [received]
PHST- 2017/02/23 00:00 [accepted]
PHST- 2017/03/02 06:00 [entrez]
PHST- 2017/03/02 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/02/28 00:00 [pmc-release]
AID - 10.1186/s13045-017-0429-8 [pii]
AID - 429 [pii]
AID - 10.1186/s13045-017-0429-8 [doi]
PST - epublish
SO  - J Hematol Oncol. 2017 Feb 28;10(1):63. doi: 10.1186/s13045-017-0429-8.